Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Large Decline in Short Interest

Allarity Therapeutics, Inc. (NASDAQ:ALLR) saw a significant decrease in short interest in the month of January. As of January 30th, there was short interest totaling 215,761 shares, a decrease of 14.7% from the January 15th total of 253,018 shares. Currently, 1.3% of the company’s stock are sold short. Based on an average daily trading volume, of 129,627 shares, the short-interest ratio is presently 1.7 days. Based on an average daily trading volume, of 129,627 shares, the short-interest ratio is presently 1.7 days. Currently, 1.3% of the company’s stock are sold short.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, January 21st. Ascendiant Capital Markets increased their target price on shares of Allarity Therapeutics from $9.25 to $9.50 and gave the stock a “buy” rating in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Allarity Therapeutics presently has an average rating of “Hold” and a consensus price target of $9.50.

Allarity Therapeutics Trading Down 1.8%

NASDAQ:ALLR opened at $0.83 on Wednesday. The stock has a market capitalization of $13.35 million, a PE ratio of -1.41 and a beta of 0.24. Allarity Therapeutics has a 1-year low of $0.61 and a 1-year high of $2.35. The firm has a fifty day simple moving average of $1.06 and a 200 day simple moving average of $1.25.

Institutional Investors Weigh In On Allarity Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC bought a new position in Allarity Therapeutics during the second quarter worth about $27,000. XTX Topco Ltd acquired a new stake in shares of Allarity Therapeutics in the second quarter valued at approximately $51,000. Geode Capital Management LLC lifted its position in shares of Allarity Therapeutics by 49.3% in the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after buying an additional 16,729 shares during the last quarter. Capital Advisors Inc. OK bought a new position in shares of Allarity Therapeutics during the 4th quarter worth approximately $108,000. Finally, DRW Securities LLC acquired a new position in shares of Allarity Therapeutics during the 4th quarter worth approximately $133,000. 11.53% of the stock is owned by institutional investors.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.